Learn More
Transcatheter aortic valve implantation (TAVI) enables treatment of aortic stenosis with no need for open heart surgery. According to current guidelines, only patients considered at high surgical risk can be treated with TAVI. In this study, patient-specific analyses were performed to explore the feasibility of TAVI in morphologies, which are currently(More)
BACKGROUND In a previous phase I-II study we demonstrated that the FOLFOXIRI regimen [irinotecan 125-175 mg/m2 day 1, oxaliplatin 100 mg/m2 day 1, l-leucovorin (l-LV) 200 mg/m2 day 1, 5-fluorouracil (5-FU) 3800 mg/m2 as a 48-h chronomodulated continuous infusion starting on day 1, repeated every 2 weeks] has promising activity and efficacy in metastatic(More)
Optimal fluid delivery from carbohydrate solutions such as oral rehydration solutions or sports drinks is essential. The aim of the study was to investigate whether a beverage containing glucose and fructose would result in greater fluid delivery than a beverage containing glucose alone. Six male subjects were recruited (average age (+/-SD): 22 +/- 2 y).(More)
The pharmacokinetics (PK) and pharmacodynamics (PD) of metronomic irinotecan have not been studied in cancer patients. The aim of the study is to investigate the PK/PD profile of irinotecan/SN-38 administered by metronomic schedule. Twenty chemotherapy-refractory or chemotherapy-resistant patients with metastatic colorectal carcinoma were enrolled.(More)
3553 Background: We conducted a phase I-II study with the triple drug combination FOLFOXIRI (irinotecan 125-175 mg/sqm day (d) 1, oxaliplatin 100 mg/sqm d1, l-LV 200 mg/sqm d1, 5-FU 3800 mg/sqm 48-h IV chronomodulated continuous infusion starting on d1, repeated every 2 weeks) and a subsequent phase II study with a simplified FOLFOXIRI regimen (irinotecan(More)
BACKGROUND We conducted two phase II trials evaluating the combination of 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) as first-line treatment in 74 metastatic colorectal cancer patients. Results were very promising with an overall response rate of 71% and 72%, a median PFS of 10.4 and 10.8 months and an overall survival of 26.5 and(More)
Modern studies undertaken to aid the understanding of the pathogenesis of pulmonary sarcoidosis have shown that the initial lesions of this disease are characterised by an accumulation of T lymphocytes and of macrophages in the alveolar structure (the alveolitis). In patients with active disease these cells are seen to be not only increased but apparently(More)